|Day Low/High||3.54 / 3.66|
|52 Wk Low/High||1.38 / 4.90|
Paul Bach Named Successor Chief Operating Officer
In recent trading, shares of Genesis Healthcare Inc have crossed above the average analyst 12-month target price of $2.67, changing hands for $2.72/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
- NueHealth Patients Now Have Access to Advanced Early Cancer Detection Tests -
Enters Into New Four Year $120 Million Term Loan Agreement; Pays Off Prior Term Loan
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
-- Centers recognized by national program for commitment to quality care --
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Genesis Healthcare, Inc.